Article Text

Download PDFPDF
E-cigarette flavour enhancers: Flavoured pod attachments compatible with JUUL and other pod-based devices
  1. Sam N Cwalina,
  2. Adam M Leventhal,
  3. Jessica L Barrington-Trimis
  1. Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
  1. Correspondence to Dr Jessica L Barrington-Trimis, Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90007, USA; jtrimis{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

JUUL labs transformed the electronic cigarette (e-cigarette) market when they introduced their innovative nicotine salt e-cigarette device in 2015.1 The sleek pod device quickly became the most commonly used tobacco product among adolescents.2 Like other products, JUUL was initially available in mango, mint and a variety of other flavours appealing to youth.3 However, due to rising pressure from the US Food and Drug Administration (FDA) and antitobacco groups, JUUL voluntarily stopped selling all flavoured pods except for menthol, mint, and tobacco in October 2019. Subsequently, after findings from a national study reported that mint flavour was the most popular JUUL flavour used among youth,3 JUUL also removed their mint flavour from the market in November 2019, leaving only menthol and tobacco flavoured pods. With millions of JUUL users—many of them youth—reporting that the variety of flavours offered was one of the most appealing aspects of the …

View Full Text


  • Twitter @SamCwalina

  • Contributors SC developed the concept, synthesised available data, wrote and edited the manuscript and approved the manuscript as submitted. AL and JB-T contributed to editing the manuscript and approved the manuscript as submitted.

  • Funding Research reported in this publication was supported by grant number U54CA180905 and R01CA229617 from the National Cancer Institute at the National Institutes of Health (NIH) and the Food and Drug Administration Center for Tobacco Products, grant number K01DA042950 from the National Institute for Drug Abuse at NIH, and grant 27-IR-0034 from the Tobacco Related Disease Research Program.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement There are no data in this work.

Linked Articles